$0.57
+0.05 (+9.00%)
Open$0.54
Previous Close$0.52
Day High$0.57
Day Low$0.52
52W High$1.83
52W Low$0.49
Volume—
Avg Volume246.7K
Market Cap46.50M
P/E Ratio—
EPS$-0.48
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+5,510.4% upside
Current
$0.57
$0.57
Target
$31.94
$31.94
$22.24
$31.94 avg
$42.20
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 15.40M | 13.64M | 13.89M |
| Net Income | -704,326 | -740,627 | -795,931 |
| Profit Margin | -4.6% | -5.4% | -5.7% |
| EBITDA | -1,183,474 | -997,072 | -1,062,628 |
| Free Cash Flow | -738,508 | -859,127 | -679,392 |
| Rev Growth | +4.1% | +16.3% | -0.4% |
| Debt/Equity | 0.22 | 0.30 | 0.23 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |